Lund, Sweden – 4 April 2018 – BioInvent International AB’s (OMXS: BINV) partner ThromboGenics has today announced initial data from a from a Phase l/ll, single-masked, multicentre study to evaluate the safety and efficacy of 2 dose levels (4 mg and 8 mg) of THR-317 for the treatment of diabetic macular edema (NCT03071068).

ThromboGenics reported initial data for the anti-VEGF treatment naive group (n=40) up to Day 90; 30 days after the last intravitreal (IVT) anti-PlGF administration. The primary focus of this study was safety outcomes. THR-317 was safe and well tolerated. No dose-limiting toxicities or relevant safety events were reported at either dose level.

ThromboGenics also announced that 30 % of the anti-VEGF treatment naive study subjects treated with THR-317 in the 8 mg group showed ≥ 15 letter gain from baseline at Day 90 versus 5.3 % in the 4 mg group.

For further information on the study, see ThromboGenic's press release of 4 April 2018 (www.thrombogenics.com).

ThromboGenics carries all costs for the development of THR-317 and BioInvent is entitled to five percent of the project's economic value.
 
 
Notes to editors:

About BioInvent 
BioInvent International AB (OMXS: BINV) is focused on the discovery and development of novel and first-in-class immuno-regulatory antibodies to treat cancer. The Company’s clinical programmes are BI- 1206, currently in a Phase I/II for non-Hodgkin’s lymphoma and chronic lymphatic leukaemia and TB- 403, in cooperation with Oncurious, currently in Phase I/II for medulloblastoma. BioInvent has an exciting pre-clinical portfolio based on novel immuno-modulatory antibodies that target regulatory T cells (T-regs) and tumour-associated myeloid cells. In December 2016, the Company signed a strategic research collaboration with Pfizer Inc. BioInvent also works with leading academic institutions including the University of Southampton, Cancer Research UK, and Penn Medicine. BioInvent generates revenues from global partnerships, including Bayer Pharma, Daiichi Sankyo, and Mitsubishi Tanabe Pharma and from its manufacturing facility for the production of antibodies for research through to late-stage clinical trials. More information is available at www.bioinvent.com

For further information, please contact:

Björn Frendéus
Acting CEO and CSO
+46 (0) 46 286 25 45
+46 (0) 708 11 25 45
[email protected]

BioInvent International AB (publ) 
Co. reg. No. 556537-7263
Visiting address: Sölvegatan 41
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
[email protected]
www.bioinvent.com 

The press release contains statements about the future, consisting of subjective assumptions and forecasts for future scenarios. Predictions for the future only apply as the date they are made and are, by their very nature, in the same way as research and development work in the biotech segment, associated with risk and uncertainty. With this in mind, the actual outcome may deviate significantly from the scenarios described in this press release.

This information is information that BioInvent International AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 9.40 a.m. CET, on 4 April 2018.